- cafead   Jul 26, 2024 at 11:32: AM
via Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European regulators.
article source
article source